Sbir topic 229, phase II: pharmacodynamic assay for AKT for use with PI3K/AKT/mtor inhibitors
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261201100087C
- Awardee
-
Rockland Immunochemicals Inc. UEI NFKNUGEMMY18
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $992,089
Award facts
- Opportunity
-
- N44CO1701873 Solicitation number
- Contract value 100% obligated
- $992,088.91 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Boyertown, PA 19512, USA
- Research
- SBIR Program Phase II Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$6,913 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $999,002 |
About this award
This is a $992,088.91 Phase II Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) Department of Health and Human Services (HHS), to Rockland Immunochemicals Inc., a for-profit small business corporation.
The contract is for the development of a "Pharmacodynamic Assay for AKT for Use with PI3K/AKT/mTOR Inhibitors" under SBIR Topic 229. As a Phase II SBIR award, this follows a previous Phase I effort and represents further research and development of the technology. The contract is a cost-plus-fixed-fee definitive contract with a period of performance through March 31, 2014.
Quick answers
Who was awarded contract HHSN261201100087C?
HHSN261201100087C was awarded to Rockland Immunochemicals Inc. by National Cancer Institute (National Institutes of Health) on September 29, 2011.
How much is contract HHSN261201100087C worth?
The government has obligated $992,089 on HHSN261201100087C. Its current value, with exercised options, is $992,089.
Was contract HHSN261201100087C competed?
The extent of competition for HHSN261201100087C was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award